MSNPs have also been studied for their use as stimuli-responsive drug release systems. In this application, the surface of MSNPs can be manipulated to adjust the controlled release of the encapsulated drug after a trigger reaction occurs. Some of the different medications that have been incorporated into MSNP-based drug delivery systems include vancomycin and adenosine triphosphate (ATP).

An Overview of Organic Nanomaterials

Several organic-based nanomaterials, including liposomes, micelles, and polymer nanoparticles, have been developed for drug delivery purposes.

Liposomes, for example, or a type of lipid-based nanomaterial that consists of an aqueous core surrounded by a phospholipid bilayer. This structure is therefore amphiphilic and allows for the formation of a thermodynamically stabilized vesicle. Some of the most common types of phospholipids that are often incorporated into liposomes include phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine, and phosphatidylglycerol. In addition to these phospholipids, stabilizers like cholesterol are also often incorporated into a liposome to increase their stability.

As drug delivery vehicles, liposomes have been shown to improve the permeation of hydrophilic drugs, protect peptides and other protein-based drugs against harsh conditions like the stomach’s acidity, improve the bioavailability of drugs, as well as reduce toxicity and adverse side effects. Notably, the targeting ability and rate of drug release of liposomes depend on the type of lipid incorporated into the liposome and their size, lamellarity, and surface properties.

Applications in Cancer Treatment

Both INPs and organic nanoparticles have been widely studied for their use as drug delivery vehicles for anticancer drugs. For example, AuNPs and IONPs and their combination have been explored for HER2 receptor-based targeting of drugs for the treatment of breast cancer.

Several other HER2-based targeting treatments have been developed based on modified nanocarriers to improve the therapeutic efficacy of specific antineoplastic agents. For example, one recent study discussed the development of trastuzumab conjugated pH-sensitive double-emulsion nanocapsules (DENCs) that are stabilized by both poly (vinyl alcohol) and magnetic nanoparticles. In this work, the researchers used these nanocarriers for the co-delivery of doxorubicin (DOX) and paclitaxel, which were found to improve the targeting ability of these drugs towards HER2 positive breast cancer cells.

The first FDA-approved nanodrug was Doxil®, which is a PEGylated liposomal DOX formulation that passively targets tumors via the enhanced permeability and retention (EPR) effect. Importantly, Doxil® is associated with significantly reduced cardiotoxicity as compared to when DOX is used alone.

Challenges

Despite the numerous advantages associated with both INPs and organic nanoparticles as drug delivery vehicles, several major challenges still account for their limited clinical use. One of the most significant issues includes the regulatory mechanisms currently in place for nanomedicines and the safety and toxicity assessments that need to be better tailored for nanomedical applications….